Abstracts Archive - Page 1515 of 2607 - ACR Meeting Abstracts

Abstract Number: 1916 • 2017 ACR/ARHP Annual Meeting
The Interferon Gamma Release Assay Is a Novel Predictor of Disease Activity in Systemic Lupus Erythematosus
Jenna Thomason¹, Christian Lood² and Grant Hughes³, ¹Medicine, University of Washington, Seattle, WA, ²Division of Rheumatology, Division of Rheumatology, Department of Medicine, University of Washington, Seattle, WA, ³Medicine/Rheumatology, University of Washington, Seattle, WA
Background/Purpose: Interferon gamma (IFN-G) is critical cytokine for defense against intracellular pathogens; it is also involved in the pathogenesis of systemic lupus erythematosus (SLE). The…
Abstract Number: 1917 • 2017 ACR/ARHP Annual Meeting
A Novel Type I Interferon Biomarker on B Cell Predicts with Disease Activity in SLE and Can be Measured By Cell Surface Tetherin (CD317)
Yasser M El-Sherbiny^1,2,3, Md Yuzaiful Md Yusof¹, Antonios Psarras¹, Elizabeth M.A. Hensor¹, Kumba Kabba¹, Alaa Mohamed^1,4, Miriam Wittmann⁵, Paul Emery^5,6 and Edward M Vital^1,5,7, ¹Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ²NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals, NHS Trust, Leeds, United Kingdom, ³Clinical Pathology dept., School of Medicine, Mansoura University, Mansoura, Egypt, ⁴Faculty of Medicine, Assiut University, Department of Rheumatology and Rehabilitation, Assiut, Egypt, ⁵NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ⁶University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds, United Kingdom, ⁷University of Leeds, Leeds, United Kingdom
Background/Purpose: SLE is an IFN-I-mediated disease with dysregulated handling of self-nuclear antigens triggering anti-viral immune mechanisms. The level of IFN-I activity appears to stratify for…
Abstract Number: 1918 • 2017 ACR/ARHP Annual Meeting
Blood Levels of Complement Split Product iC3b and C3 Outperform Traditional Biochemical Measures of SLE Disease Activity in Associating with Active and Clinically Meaningful Changes
Alfred Kim¹, Deepali Sen², Vibeke Strand³, Qiang John Fu⁴, Nancy Mathis¹, Martin Schmidt⁵, Robin Bruchas⁶, Nick Staten⁶, Paul Olson⁶, Chad Stiening⁶ and John Atkinson¹, ¹Rheumatology, Washington University School of Medicine, Saint Louis, MO, ²Division of Rheumatology, Washington University School of Medicine, St. Louis, MO, ³Stanford University, Palo Alto, CA, ⁴Biostatistics, Saint Louis University, Saint Louis, MO, ⁵Kypha, Inc., St. Louis, MO, ⁶Kypha, Inc., Saint Louis, MO
Background/Purpose: A major unmet need in SLE is the identification of a biomarker that consistently tracks with disease activity. One current approach is measuring complement…
Abstract Number: 1919 • 2017 ACR/ARHP Annual Meeting
The SLE-Key Test Detects an SLE Serologic Signature That Persists over Time and Is Independent of Disease Activity
Chaim Putterman¹, Michelle Petri², Roberto Caricchio³, Jim C. Oates⁴, Pennina Safer⁵, Keren Jakobi-Brook⁵, Rachel Sorek⁵, Ilana Gluzman⁵, Steve Wallace⁶ and Irun R. Cohen^5,7, ¹Division of Rheumatology, Albert Einstein College of Medicine, Bronx, NY, USA, Bronx, NY, ²Medicine (Rheumatology), Division of Rheumatology, Johns Hopkins University School of Medicine, MD, USA, Baltimore, MD, ³Temple Lupus Clinic, Temple University, Philadelphia, PA, USA, Philadelphia, PA, ⁴Division of Rheumatology & Immunology, Department of Medicine, Medical University of South Carolina, Charleston, SC, ⁵ImmunArray Ltd., Rehovot, Israel, Rehovot, Israel, ⁶ImmunArray Inc., VA, USA, Richmond, VA, ⁷Weizmann Institute of Science, Rehovot, Israel, Rehovot, Israel
Background/Purpose: We have developed the iCHIP1,2 to profile repertoires of serum autoantibodies. The first iCHIP application was the SLE-key RuleOut test3,4 , to rule out…
Abstract Number: 1920 • 2017 ACR/ARHP Annual Meeting
Tacrolimus Induces Remission in Refractory and Relapsing Lupus Nephritis By Decreasing P-Glycoprotein Expression and Function on Peripheral Blood Lymphocytes
Vikas Gupta, Sukesh Edavalath, Mohit Kumar Rai, Harshit Singh, Saurabh Chaturvedi and Vikas Agarwal, Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India
Background/Purpose: About 15-30% of Lupus Nephritis (LN) patients do not respond to first-line immunosuppressive therapy. P-glycoprotein (P-gp) mediated efflux of corticosteroids (CS) may contribute to…
Abstract Number: 1921 • 2017 ACR/ARHP Annual Meeting
Urine Angiostatin and VCAM-1 Surpass Conventional Metrics in Predicting Elevated Renal Pathology Activity Indices in Lupus Nephritis
Samar Soliman^1,2, Fatma Mohamed³, Faten Ismail³, Ramesh Saxena⁴ and Chandra Mohan², ¹Rheumatology and rehabilitation, University of Minya, Minya, Egypt, ²Biomedical Engineering, University of Houston, Houston, TX, ³Rheumatology and Rehabilitation, University of Minya, Minya, Egypt, ⁴Internal Medicine/Division of Nephrology, University of Texas Southwestern Medical Center, Dallas, TX
Background/Purpose: The goal of this study is to investigate how urinary angiostatin, VCAM-1 and established measures of renal function relate to specific histologic findings in…
Abstract Number: 1922 • 2017 ACR/ARHP Annual Meeting
Cell Type Specific Gene Expression Analysis of Early Systemic Sclerosis Skin Shows a Prominent Activation Pattern of Innate and Adaptive Immune System in the Prospective Registry for Early Systemic Sclerosis (PRESS) Cohort
Shervin Assassi¹, Dinesh Khanna², Monique Hinchcliff³, Virginia D. Steen⁴, Faye Hant⁵, Jessica K. Gordon⁶, Ami A. Shah⁷, Jun Ying⁸, William Swindell⁹, Wenjin Zheng¹⁰, Lisha Zhu¹⁰, Victoria K. Shanmugam¹¹, Robyn T. Domsic¹², Flavia V. Castelino¹³, Elana J. Bernstein¹⁴ and Tracy M. Frech¹⁵, ¹University of Texas McGovern Medical School, Houston, TX, ²University of Michigan, Ann Arbor, MI, ³Rheumatology, Northwestern Medicine, Chicago, IL, ⁴Rheumatology, MedStar Georgetown University Hospital, Washington, DC, ⁵Medicine/Rheumatology & Immunology, Medical University of South Carolina, Charleston, SC, ⁶Rheumatology, Hospital for Special Surgery, New York, NY, ⁷Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁸Department of Internal Medicine - Rheumatology, University of Texas McGovern Medical School, Houston, TX, ⁹Dermatology, University of Michigan - Ann Arbor, Ann Arbor, MI, ¹⁰University of Texas - School of Biomedical Informatics, Houston, TX, ¹¹Rheumatology, The George Washington University, Washington, DC, ¹²Rheumatology, University of Pittsburgh, Pittsburgh, PA, ¹³Rheumatology, Harvard Medical School, Boston, MA, ¹⁴Rheumatology, Columbia University, New York, NY, ¹⁵Division of Rheumatology, University of Utah, Salt Lake City, UT
Background/Purpose: To examine the global gene expression profile in patients with very early diffuse systemic sclerosis (SSc). Methods: Skin biopsies were obtained from patients enrolled…
Abstract Number: 1923 • 2017 ACR/ARHP Annual Meeting
Single Cell RNA Sequencing Reveals a Signature of Endothelial Injury in Scleroderma Skin
Sokratis Apostolidis¹, Giuseppina Stifano², Tracy Tabib³, Lisa Rice², Christina Morse³, Bashar Kahaleh⁴ and Robert A. Lafyatis³, ¹Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA, ²Boston University School of Medicine, Boston, MA, ³Medicine, Rheumatology, University of Pittsburgh Medical Center, Pittsburgh, PA, ⁴Medicine/Rheumatology, University of Toledo, Toledo, OH
Background/Purpose: Vascular injury is a hallmark event in the pathogenesis of Systemic Sclerosis (SSc). Endothelial dysfunction happens early in the course of the disease and…
Abstract Number: 1924 • 2017 ACR/ARHP Annual Meeting
The Nuclear Receptor ROR-Alpha As a Key Checkpoint of Tissue Repair
Rosebeth Kagwiria¹, Ruifang Liang², Chih-Wei Chen³, Thomas Burris⁴, Georg Schett⁵ and Jörg Distler⁶, ¹Department of Internal Medicine 3 and Institute for Clinical Immunology, Friedrich-Alexander-University of Erlangen-Nuremberg and University Hospital Erlangen, Erlangen, Germany, ²Department of Internal Medicine 3 – Rheumatology and Immunology, Universitätsklinikum Erlangen, Department of Internal Medicine 3 and Institute for Clinical Immunology, Friedrich-Alexander-University of Erlangen-Nuremberg and University Hospital Erlangen, Erlangen, Germany, ³Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and University Hospital Erlangen, Erlangen, Germany, Erlangen, Germany, ⁴Department of pharmacology and physiology, Saint Luis University-school of medicine, Florida, USA, St. Louis, Missouri, MO, ⁵Department of Internal Medicine 3 – Rheumatology and Immunology, Department of Internal Medicine 3 and Institute for Clinical Immunology, Friedrich-Alexander-University of Erlangen-Nuremberg and University Hospital Erlangen, Erlangen, Germany, ⁶Department of Internal Medicine 3 – Rheumatology and Immunology, Universitätsklinikum Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Erlangen, Germany
Background/Purpose: The Retinoic-acid related Orphan Receptor-alpha (RORα) is a member of the nuclear receptor superfamily and a ligand-dependent transcription factor implicated in a wide range…
Abstract Number: 1925 • 2017 ACR/ARHP Annual Meeting
TGFβ Promotes Fibrosis By MYST1-Dependent Epigenetic Regulation of Autophagy
Ariella Zehender¹, Neng-Yu Lin², Adrian Stefanica³, Chih-Wei Chen⁴, Alina Soare⁵, Thomas Wohlfahrt⁶, Simon Rauber⁶, Christina Bergmann⁷, Andreas Ramming⁸, Oliver Distler⁹, Georg Schett¹⁰ and Jörg Distler⁵, ¹1Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and University Hospital Erlangen, Erlangen, Germany, ²Department of Internal Medicine III and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ³1Department of Internal Medicine 3 – Rheumatology and Immunology, University of Erlangen, Erlangen, Germany, ⁴Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and University Hospital Erlangen, Erlangen, Germany, Erlangen, Germany, ⁵Department of Internal Medicine 3 – Rheumatology and Immunology, Universitätsklinikum Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Erlangen, Germany, ⁶Department of Internal Medicine 3, Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and University Hospital Erlangen, Erlangen, Germany, ⁷Department of Internal Medicine 3 and Institute for Clinical Immunology, Friedrich-Alexander-University of Erlangen-Nuremberg and University Hospital Erlangen, Erlangen, Germany, ⁸Department of Internal Medicine 3 – Rheumatology and Immunology, Universitätsklinikum Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and University Hospital Erlangen, Erlangen, Germany, ⁹Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland, ¹⁰Department of Internal Medicine 3 – Rheumatology and Immunology, Department of Internal Medicine 3 and Institute for Clinical Immunology, Friedrich-Alexander-University of Erlangen-Nuremberg and University Hospital Erlangen, Erlangen, Germany
Background/Purpose: Autophagy (Atg) is catabolic process allowing cells to degrade unnecessary or dysfunctional cellular organelles. Aberrant activation of Atg has been implicated into the pathogenesis…
Abstract Number: 1926 • 2017 ACR/ARHP Annual Meeting
Cardiac Remodeling in Systemic Sclerosis: TGF-β/Fra2-Dependent Autophagy As a Novel Target for Heart Fibrosis
Mara Stellato¹, Michal Rudnik¹, Florian Renoux¹, Elena Pachera¹, Karl Sotlar², Karin Klingel³, Joerg C. Henes⁴, Przemyslaw Blyszczuk^1,5, Oliver Distler¹ and Gabriela Kania¹, ¹Department of Rheumatology, Center of Experimental Rheumatology, University Hospital Zurich, Zurich, Switzerland, ²Institute of Pathology, Ludwig Maximilians University, Munich, Germany, ³Department of Molecular Pathology, University Hospital Tuebingen, Tuebingen, Germany, ⁴Department of Internal Medicine II, Division of Rheumatology, University Hospital Tuebingen, Tuebingen, Germany, ⁵Department of Clinical Immunology, Jagiellonian University Medical College, Krakow, Poland
Background/Purpose: SSc patients frequently suffer from primary cardiac involvement. The main histological feature is fibrosis, but the mechanisms responsible for the heart failure remain unclear.…
Abstract Number: 1927 • 2017 ACR/ARHP Annual Meeting
Anti-Fibrotic Mechanisms of Endostatin-Derived Peptide Are the Result of Reduction in Pro-Fibrotic Mediators and Promotion of Extracellular Matrix Degradation
Tomoya Watanabe¹, Tetsuya Nishimoto², Takahisa Takihara³, Logan Mlakar⁴, Yunyun Su⁵ and Carol A. Feghali-Bostwick⁶, ¹Rheumatology, Medical University of South Carolina, Charleston, SC, ²Division of Rheumatology and Immunology, Medical University of South Carolina, Charleston, SC, ³Division of Pulmonary Medicine, Tokai University School of Medicine, Isehara, Japan, ⁴Medical University of South Carolina, Charleston, SC, ⁵Medicine, Division of Rheumatology and Immunology, Medical University of South Carolina, charleston, SC, ⁶Division of Rheumatology and Immunology, Division of Rheumatology and Immunology, Medical University of South Carolina, Charleston, SC, United States, Charleston, SC
Background/Purpose: Fibrotic disorders such as systemic sclerosis (SSc) result in end-stage organ failure and loss of function, consequently causing high morbidity and mortality. We recently…
Abstract Number: 1928 • 2017 ACR/ARHP Annual Meeting
Fibroblast-like Synovial Cell Production of ED-a Fibronectin Contributes to Inflammation in Osteoarthritis
Tue Wenzel Kragstrup^1,2,3, Dong Hyun Sohn⁴, Christin Lepus³, Kazuhiro Onuma⁵, Qian Wang³, William H. Robinson³ and Jeremy Sokolove³, ¹Randers Regional Hospital, Randers, Denmark, ²Department of Biomedicine, Aarhus University, Aarhus, Denmark, ³VA Palo Alto Healthcare System and Stanford University, Palo Alto, CA, ⁴Microbiology and Immunology, Pusan National University School of Medicine, Yangsan, Korea, Republic of (South), ⁵VA Palo Alto Healthcare System and Stanford University, Stanford, CA
Background/Purpose: The pathophysiology of osteoarthritis (OA) involves wear and tear, and a state of low-grade inflammation. Wear and tear leads to tissue degradation followed by…
Abstract Number: 1929 • 2017 ACR/ARHP Annual Meeting
Sustained Efficacy of Intra-Articular SB-061, a Novel Matrix Regulator Inspired By Aggrecan, in a Rat Model of Osteoarthritis
Kate Stuart¹, Julia Chen¹, Sharmi Saha¹, Harsha Kabra¹, Athene Chan¹, Kamal Egodoge¹, Jennifer Oskins², Chaohua Lin², Morten Karsdal³, Mark Chambers² and John Paderi¹, ¹Symic Bio, Emeryville, CA, ²Lilly Research Laboratories, Indianapolis, IN, ³Biomarkers and Reseacrh, Nordic Bioscience, Herlev, Denmark
Background/Purpose: No therapy for osteoarthritis (OA) has yet to deliver both structural and symptomatic benefits. Symic is approaching this unmet clinical need with a novel…
Abstract Number: 1930 • 2017 ACR/ARHP Annual Meeting
Interleukin 1β Decreases Capacity for Repair Human Cartilage Lesions By Mesenchymal Stromal Cells on Collagen/Proteoglycan Scaffolds
Clara Sanjurjo-Rodríguez¹, ROCÍO CASTRO-VIÑUELAS², Tamara Hermida-Gómez³, ISAAC FUENTES BOQUETE⁴, Francisco Javier De Toro Santos⁵, Francisco J Blanco⁶ and SILVIA MARIA DÍAZ-PRADO⁴, ¹of Biomedical Sciences, Medicine and Physiotherapy., Cell Therapy and Regenerative Medicine Group. Universidade da Coruña. INIBIC. CIBER-BBN., A CORUÑA, Spain, ²Biomedical Sciences. Medicine and Physiotherapy, Cell Therapy and Regenerative Medicine Group. Universidade da Coruña. INIBIC., A CORUÑA, Spain, ³Rheumatology, INIBIC. Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas. CIBER-BBN., A Coruña, Spain, ⁴Biomedical Sciences, Medicine and Physiotherapy, Cell Therapy and Regenerative Medicine Group. Universidade da Coruña. INIBIC. CIBER-BBN., A CORUÑA, Spain, ⁵Reumatology, Cell Therapy and Regenerative Medicine Group. Universidade da Coruña. INIBIC. CIBER-BBN. Complejo Hospitalario Universitario A Coruña (SERGAS)., La Coruña, Spain, ⁶Servicio de Reumatología. Area Genomica. Instituto de Investigación Biomédica de A Coruña (INIBIC). Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC), A Coruña, Spain
Background/Purpose: There is controversy about the effect of catabolic cytokines in regenerative medicine. The purpose of this study was to evaluate the effect of interleukin…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].